Moss-made Biopharmaceuticals

NEXT GENERATION THERAPEUTICS FOR ORPHAN DISEASES

MOSS-AGAL FOR FABRY DISEASE

CLINICAL TRIAL COMPLETED

After successful preclinical studies, Greenovation’s first drug candidate moss-aGal phase I clinical trial is completed

Learn more

MOSS-FH FOR C3G DISEASE

PRECLINICAL TRIAL

A recombinant protein in development as a treatment for patients suffering from C3 Glomerulopathy (C3G)

Learn more

PRODUCTS IN DEVELOPMENT

DEVELOPMENTAL PIPELINE

Based on our innovative BryoTechnology platform, we have established a pipeline of proprietary clinical candidates

Learn more

BryoTechnology

KNOWN PROCEDURES – BETTER PRODUCTS

Greenovation offers the full range of contract development and manufacturing from small-scale feasibility studies to validated clinical- and commercial-scale production processes

BryoTechnology: KNOWN PROCEDURES – BETTER PRODUCTS

Strain Development

Production Process

Products/ Therapies

Learn more

Latest news

Greenovation Biotech GmbH reports positive clinical data from the Phase 1 safety study for moss-aGal

Read more

Upcoming Events

49. Jahrestagung der Gesellschaft für Pädiatrische Nephrologie

Hannover, Germany

February. 28. – 02. 03. 2018

Read more

Do it in moss!

BryoTechnology offers a wide range of advantages for biopharmaceutical development and production processes. Our broad IP portfolio covers plant production processes, N-glycosylation techniques, proprietary drug candidates, and mechanisms-of-action. We offer contract manufacturing and licensing models.

What can we do for you?